玛伐凯泰对中国症状性梗阻性肥厚型心肌病患者的影响:EXPLORER-CN随机临床试验
该研究为在中国12家医院开展的3期随机双盲安慰剂对照试验,纳入81例LVOT压差≥50 mmHg且NYHA II或III级的梗阻性肥厚型心肌病患者,按2:1随机接受玛伐凯泰(起始2.5 mg每日一次)或安慰剂治疗30周。
要点
- 玛伐凯泰显著降低中国oHCM患者Valsalva LVOT峰值压差,较安慰剂最小二乘均值差-70.3 mmHg。
- 玛伐凯泰组48.1%患者Valsalva LVOT峰值压差<30 mmHg,安慰剂组仅3.7%。
- 玛伐凯泰安全性与安慰剂相似,无患者出现LVEF<50%,无新安全信号。
核心结论
- 玛伐凯泰显著改善中国症状性oHCM患者的Valsalva LVOT峰值压差,所有次要疗效终点亦改善,安全性与安慰剂相似。
研究设计与样本
- 3期随机双盲安慰剂对照试验,在中国12家医院开展,2022年1月4日至8月5日入组,治疗30周。
- 纳入81例oHCM患者,LVOT压差≥50 mmHg且NYHA II或III级,按2:1随机接受玛伐凯泰(起始2.5 mg每日一次)或安慰剂。
- 主要终点为Valsalva LVOT峰值压差从基线至第30周的变化,按意向性治疗分析。
主要发现
- 静息LVOT峰值压差最小二乘均值差为-55.0 mmHg(95%CI -69.1至-40.9)。
- 第30周Valsalva LVOT峰值压差<30 mmHg者玛伐凯泰组48.1%(26/54)vs安慰剂组3.7%(1/27);<50 mmHg者59.3%(32/54)vs 7.4%(2/27);NYHA分级改善者59.3%(32/54)vs 14.8%(4/27)。
- KCCQ临床总结评分最小二乘均值差10.2(95%CI 4.4-16.1),NT-proBNP几何均值比值0.18(95%CI 0.13-0.24),hs-cTnI几何均值比值0.34(95%CI 0.27-0.42),LVMI平均差-30.8 g/m2(95%CI -41.6至-20.1)。
- 安全性与耐受性在玛伐凯泰与安慰剂间相似,无患者出现LVEF<50%。
临床怎么用
- 对于中国症状性oHCM且LVOT压差≥50 mmHg、NYHA II或III级的患者,玛伐凯泰可显著降低LVOT压差并改善症状与生活质量。
- 治疗期间需监测LVEF,本试验中无患者LVEF降至50%以下,安全性与安慰剂相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Mavacamten has shown clinical benefits in global studies for patients with obstructive hypertrophic cardiomyopathy (oHCM), but evidence in the Asian population is lacking. OBJECTIVE: To evaluate the safety and efficacy of mavacamten compared with placebo for Chinese patients with symptomatic oHCM. DESIGN, SETTING, AND PARTICIPANTS: This phase 3, randomized, double-blind, placebo-controlled clinical trial was conducted at 12 hospitals in China. Between January 4 and August 5, 2022, patients with oHCM and a left ventricular outflow tract (LVOT) gradient of 50 mm Hg or more and New York Heart Association (NYHA) class II or III symptoms were enrolled and received treatment for 30 weeks. INTERVENTIONS: Patients were randomized 2:1 to receive mavacamten (starting at 2.5 mg once daily) or placebo for 30 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was change in Valsalva LVOT peak gradient from baseline to week 30. Left ventricular outflow tract gradients and left ventricular ejection fraction (LVEF) were assessed by echocardiography, while left ventricular mass index (LVMI) was determined by cardiac magnetic resonance imaging. Analysis was performed on an intention-to-treat basis. RESULTS: A total of 81 patients (mean [SD] age, 51.9 [11.9] years; 58 men [71.6%]) were randomized. Mavacamten demonstrated a significant improvement in the primary end point compared with placebo (least-squares mean [LSM] difference, -70.3 mm Hg; 95% CI, -89.6 to -50.9 mm Hg; 1-sided P < .001). Similar trends were demonstrated for resting LVOT peak gradient (LSM difference, -55.0 mm Hg; 95% CI, -69.1 to -40.9 mm Hg). At week 30, more patients receiving mavacamten than placebo achieved a Valsalva LVOT peak gradient less than 30 mm Hg (48.1% [26 of 54] vs 3.7% [1 of 27]), less than 50 mm Hg (59.3% [32 of 54] vs 7.4% [2 of 27]), and NYHA class improvement (59.3% [32 of 54] vs 14.8% [4 of 27]). Greater improvements were also observed with mavacamten regarding the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (LSM difference, 10.2; 95% CI, 4.4-16.1), N-terminal pro-B-type natriuretic peptide level (proportion of geometric mean ratio, 0.18; 95% CI, 0.13-0.24), high-sensitivity cardiac troponin I level (proportion of geometric mean ratio, 0.34; 95% CI, 0.27-0.42), and LVMI (mean difference, -30.8 g/m2; 95% CI, -41.6 to -20.1 g/m2). Safety and tolerability were similar between mavacamten and placebo. No patients experienced LVEF less than 50%. CONCLUSIONS: Mavacamten significantly improved Valsalva LVOT gradient vs placebo for Chinese patients. All secondary efficacy end points were also improved. Mavacamten was well tolerated with no new safety signals. This study supports the efficacy and safety of mavacamten in diverse populations, including Chinese patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05174416.
引用
- Tian Z, Li L, Li X, et al. Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial. JAMA Cardiol. 2023. PMID: 37639259. doi:10.1001/jamacardio.2023.3030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。